Harnessing preexisting influenza virus-specific immunity increases antibody responses against SARS-CoV-2
Journal of Virology · 2024
DOI: 10.1128/jvi.01571-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, 2024. Verfasst von Harrison Dulin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Plant Pathology, University of California, Riverside, California, USA. Hauptthemen laut MEDLINE: Influenza Vaccines, COVID-19 Vaccines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NINDS NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Increased globalization and changes in human interactions with wild animals has increased the likelihood of the emergence of novel viruses with pandemic potential. Vaccines can be effective in preventing severe disease caused by pandemic viruses. However, it takes time to develop protective immunity via prime-boost vaccination. More effective vaccine designs should quickly induce protective immunity. We propose leveraging preexisting immunity to a different pathogen to boost protection against emerging viruses. We targeted SARS-CoV-2 as a representative pandemic virus and generated a fusion protein vaccine that combines the nucleoprotein from influenza A virus and the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Our vaccine design significantly increased the production of RBD-specific antibodies in mice that had previously been exposed to influenza virus, compared to those without previous exposure. This enhanced immunity reduced SARS-CoV-2 replication in mice. Our results offer a vaccine design that could be valuable in a future pandemic setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Plant Pathology, University of California, Riverside, California, USA.
- Cell, Molecular, and Developmental Biology Graduate Program, University of California, Riverside, California, USA.
- Texas Biomedical Research Institute, San Antonio, Texas, USA.
- Division of Biomedical Sciences, School of Medicine, University of California, Riverside, California, USA.
ORCID-Profile: Harrison Dulin, Emma H Wilson, Luis Martinez-Sobrido, Rong Hai
Förderung
- NIAID NIH HHS
- NINDS NIH HHS
- HHS | NIH | National Institute of Allergy and Infectious Diseases
- HHS | NIH | OSC | Common Fund
Zitieren
APA
Dulin, H., Barre, R. S., Xu, D., Neal, A., Vizcarra, E., Chavez, J., Ulu, A., Yang, M. S., Khan, S. R., Wuang, K., Bhakta, N., Chea, C., Wilson, E. H., Martinez-Sobrido, L., & Hai, R. (2024). Harnessing preexisting influenza virus-specific immunity increases antibody responses against SARS-CoV-2. Journal of Virology. https://doi.org/10.1128/jvi.01571-23
Vancouver
Dulin H, Barre RS, Xu D, Neal A, Vizcarra E, Chavez J, et al. Harnessing preexisting influenza virus-specific immunity increases antibody responses against SARS-CoV-2. Journal of Virology. 2024. doi:10.1128/jvi.01571-23
BibTeX
@article{Dulin2024,
author = {Dulin, Harrison and Barre, Ramya S and Xu, Duo and Neal, Arrmund and Vizcarra, Edward and Chavez, Jerald and Ulu, Arzu and Yang, Myeon-Sik and Khan, Siddiqur Rahman and Wuang, Keidy and Bhakta, Nikhil and Chea, Chanvoraboth and Wilson, Emma H and Martinez-Sobrido, Luis and Hai, Rong},
title = {Harnessing preexisting influenza virus-specific immunity increases antibody responses against SARS-CoV-2},
journal = {Journal of Virology},
year = {2024},
doi = {10.1128/jvi.01571-23}
}
EUVIMED